You are the news now

THE NEWS COMMENTER

VOTE  (0)  (0)

RedHill Biopharma Expands U.S.-Based Manufacturing Capacity of Opaganib for COVID-19

Added 11-29-20 10:04:02pm EST - “RedHill Biopharma Ltd. (Nasdaq: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced partnerships with two leading, U.S.-based manufacturers for large-scale manufacturing of opaganib[1]. These…” - News.yahoo.com

CLICK TO SHARE

Posted By TheNewsCommenter: From News.yahoo.com: “RedHill Biopharma Expands U.S.-Based Manufacturing Capacity of Opaganib for COVID-19”. Below is an excerpt from the article.

RedHill adds two more manufacturing partners, both U.S.-based, for large-scale manufacturing of opaganib, in preparation for potential emergency use applications as early as Q1/2021

The new collaborations follow recently announced collaborations with European and Canadian manufacturers

U.S. Phase 2 study fully enrolled – top-line data expected in the coming weeks; parallel global Phase 2/3 study more than 50% enrolled – top-line data expected Q1/2021

Opaganib's promising novel mechanism of action potentially minimizes likelihood of resistance due to viral mutations

TEL AVIV, Israel and RALEIGH, N.C., Nov. 30, 2020 /PRNewswire/ -- RedHill Biopharma Ltd. (Nasdaq: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced partnerships with two leading, U.S.-based manufacturers for large-scale manufacturing of opaganib[1]. These collaborations further advance ongoing preparations to support potential emergency use applications for opaganib to treat severe COVID-19 pneumonia, expected as early as the first quarter of 2021. The new collaborations follow recently announced collaborations with European and Canadian manufacturers.

Read more...

If you don't see any comments yet, congrats! You get first comment. Be nice and have fun.

CLICK TO SHARE

BACK TO THE HOME-PAGE